GHS Cancer Institute is a clinical research site located in Greenville, South Carolina, United States 29605.
Crixeo Health Trust Score: 75/100 (FAIR). This profile has not yet been claimed by the site owner.
GHS Cancer Institute has participated in 9 clinical trials.
Therapeutic areas: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Pancreatic Ductal.
Sponsors: Pfizer, Sumitomo Pharma America, Inc., Bristol-Myers Squibb.
Trust Score: 75/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
GHS Cancer Institute has a Crixeo Trust Score of 75/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
GHS Cancer Institute has 9 clinical trials on record. Their work covers Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Pancreatic Ductal.
Yes — GHS Cancer Institute holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.